1. Home
  2. PVLA vs FMBH Comparison

PVLA vs FMBH Comparison

Compare PVLA & FMBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • FMBH
  • Stock Information
  • Founded
  • PVLA 2015
  • FMBH 1865
  • Country
  • PVLA United States
  • FMBH United States
  • Employees
  • PVLA N/A
  • FMBH N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • FMBH Major Banks
  • Sector
  • PVLA Health Care
  • FMBH Finance
  • Exchange
  • PVLA Nasdaq
  • FMBH Nasdaq
  • Market Cap
  • PVLA 888.0M
  • FMBH 974.1M
  • IPO Year
  • PVLA N/A
  • FMBH N/A
  • Fundamental
  • Price
  • PVLA $81.40
  • FMBH $36.16
  • Analyst Decision
  • PVLA Strong Buy
  • FMBH Hold
  • Analyst Count
  • PVLA 13
  • FMBH 5
  • Target Price
  • PVLA $99.38
  • FMBH $43.20
  • AVG Volume (30 Days)
  • PVLA 163.2K
  • FMBH 72.6K
  • Earning Date
  • PVLA 11-11-2025
  • FMBH 10-30-2025
  • Dividend Yield
  • PVLA N/A
  • FMBH 2.69%
  • EPS Growth
  • PVLA N/A
  • FMBH 12.54
  • EPS
  • PVLA N/A
  • FMBH 3.65
  • Revenue
  • PVLA N/A
  • FMBH $335,099,000.00
  • Revenue This Year
  • PVLA N/A
  • FMBH N/A
  • Revenue Next Year
  • PVLA N/A
  • FMBH $13.60
  • P/E Ratio
  • PVLA N/A
  • FMBH $10.20
  • Revenue Growth
  • PVLA N/A
  • FMBH 5.91
  • 52 Week Low
  • PVLA $11.17
  • FMBH $27.58
  • 52 Week High
  • PVLA $85.30
  • FMBH $43.86
  • Technical
  • Relative Strength Index (RSI)
  • PVLA 59.88
  • FMBH 43.48
  • Support Level
  • PVLA $78.99
  • FMBH $36.39
  • Resistance Level
  • PVLA $85.03
  • FMBH $37.78
  • Average True Range (ATR)
  • PVLA 5.58
  • FMBH 0.95
  • MACD
  • PVLA -0.02
  • FMBH 0.10
  • Stochastic Oscillator
  • PVLA 63.39
  • FMBH 47.09

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

About FMBH First Mid Bancshares Inc.

First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.

Share on Social Networks: